Effects of Photobiomodulation on Pain and Sexual Function in Women With Dyspareunia: Randomized Clinical Trial
52 patients around the world
Available in Brazil
Female sexual dysfunction is known as the disorder experienced by a woman when changes occur
in her usual sexual behavior. It is estimated that between 16 and 40% of women suffer from
some form of sexual dysfunction, and this percentage increases with age.1 Among the painful
disorders, dyspareunia stands out, which is defined as pain perceived in the pelvis
associated with sex with penetration. It can be applied to women and men. It usually occurs
with penile penetration, but is often associated with pain during the insertion of any
object. It can apply to anal and vaginal intercourse. It is classically subdivided into
superficial, when it affects the vulva and vaginal entrance, and deep, when the painful area
is the cervix, bladder and/or the lower part of the pelvis.2 Another classification divides
it into primary, associated with pain at the beginning of sexual life, and secondary, when it
appears later.3 It directly affects physical health, as well as sexual and mental well-being.
Consequently, it can lead to depression, anxiety and low self-esteem in women who experience
it.4 Studies show an association between hyperactivity of the pelvic muscles and dyspareunia,
which can have a significant impact on physical and mental health, leading to problems such
as depression, anxiety, hypervigilance to pain, negative body image and low self-esteem, in
addition to the possibility of leading to other sexual dysfunctions.5 Multidisciplinary
treatment is highly recommended in this population and aims to address the various physical,
emotional and behavioral aspects involved in sexual dysfunctions. This approach involves the
collaboration of a team made up of specialized professionals, such as gynecologists,
physiotherapists, sex therapists, psychologists and/or psychiatrists. Among these
professionals, physiotherapy stands out as an intervention capable of improving sexual
health, through individualized approaches for each patient. Considering that many patients
with dyspareunia do not respond adequately to conventional drug therapy, there is a clear
need to seek new therapeutic alternatives, such as photobiomodulation (PBM). Previous studies
show positive results in the use of PBM in improving pain related to musculoskeletal and
arthritic conditions. Furthermore, the application of PBM in the area of pelvic physiotherapy
has been expanded. A study carried out by Lev-Sagie et al.6 showed positive results in the
use of photobiomodulation in women with vestibulodynia, in relation to pain. Previous studies
also indicate that intravaginal application of PBM has been effective in alleviating pain in
conditions related to chronic pelvic pain, endometriosis, and pelvic pain of myofascial
origin, which suggests that photobiomodulation may be a promising therapy for women with
dyspareunia.7 ,8,9 In recent years, research has been carried out to investigate the presence
and increase of inflammatory mediators in different painful musculoskeletal disorders10-14. A
study that applied photobiomodulation to patients with low back pain observed changes in some
biomarkers, in plasma or microdialysate, indicating that patients with low back pain who
receive photobiomodulation may present changes in the levels of inflammatory mediators.15 But
to date, few studies have been carried out on this topic, none of them applied to women with
dyspareunia The scarcity of studies standardizing an application protocol, which observes
time of effect and analysis of inflammatory biomarkers in the use of photobiomodulation in
women with dyspareunia, justifies the need for research on the topic. Therefore, the
objective of this study is to compare the effects of vulvar and intravaginal application of
PBM compared to the sham group on the pain and sexual function of women with dyspareunia in
the immediate post-intervention moments and in follow-ups of 15, 30, 90 and 180 days.
Federal University of Health Science of Porto Alegre
1Research sites
52Patients around the world
This study is for people with
Genito-pelvic pain disorders
Dyspareunia
Requirements for the patient
To 45 Years
Female
Medical requirements
Women, aged between 18 and 45 years classified with dyspareunia criteria, according to the guidelines of the European Association of Urology guideline (2022)2, who report pain in relationship greater than 3 on the visual numeric pain scale at the beginning of participation in the research, who present sensitivity to unidigital palpation of the pelvic muscular wall (e.g., levator ani, coccygeus, obturator) and who report feeling pain during penetration for at least 6 months.
Women with a history of neurological or oncological diseases or bone fractures in the pelvic region, in addition to radiculopathies, decompensated heart disease or metabolic disorders, pregnant women, lactating women, women in menopause, women with difficulties in understanding written or spoken language, in use of photosensitizing drugs, who present an inflammatory condition or have used anti-inflammatories on the day of the evaluation, red flags (post-coital bleeding, abrupt unexplained weight loss, presence of a mass visible on ultrasound, macroscopic or microscopic hematuria), who have a diagnosis of painful bladder syndrome, irritable bowel syndrome, interstitial cystitis, fibromyalgia.
Who have a history of spine surgery or have undergone any surgical intervention with general anesthesia in the last 120 days. Who is currently undergoing pelvic physiotherapy treatment.
Sites
Universidade Federal de Ciências da Saúde de Porto Alegre
R. Sarmento Leite, 245 - Centro Histórico, Porto Alegre - RS, 90050-170, Brazil
SponsorFederal University of Health Science of Porto Alegre